rss
Br J Ophthalmol 2006;90:1370-1373 doi:10.1136/bjo.2006.094326
  • Clinical science
    • Extended reports

Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

  1. L B Cantor,
  2. J Hoop,
  3. L Morgan,
  4. D WuDunn,
  5. Y Catoira,
  6. The Bimatoprost–Travoprost Study Group
  1. Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA
  1. Correspondence to: L B Cantor Department of Ophthalmology, Indiana University Medical Center, 702 Rotary Circle, Indianapolis, IN 46202, USA;lcantor{at}iupui.edu
  • Accepted 2 June 2006
  • Published Online First 6 July 2006

Abstract

Aim: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension.

Methods: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months.

Results: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p≥0.741). After 6 months, both drugs significantly reduced IOP at every time point (p≤0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups.

Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.

Footnotes

  • Published Online First 6 July 2006

  • The Bimatoprost–Travoprost Study Group included: Thomas Bournias, Northwestern University, Chicago, Illinois; Louis Cantor, Indiana University School of Medicine, Indianapolis, Indiana; Monte Dirks, Black Hills Regional Eye Institute, Rapid City, South Dakota; Efraim Duzman, Lakeside Vision Center, Irvine, California; Arash Mansouri, Access Eye Centers, Fredericksburg, Virginia; Thomas Mundorf, Mundorf Eye Center, Charlotte, North Carolina; Steven Simmons, Glaucoma Consultants of the Capital Region, Slingerlands, New York; Robert Williams, Taustine Eye Center, Louisville, Kentucky.

  • Funding: This study was supported by an unrestricted educational grant from Allergan, Irvine, California, USA.

  • Competing interests: Dr Cantor is a consultant for and has received speaker honoraria from Allergan, and research support from Allergan, Alcon and Pfizer. Dr WuDunn is a consultant for and has received speaker honoraria from Alcon and research support from Alcon and Pfizer. Dr Catoira has received speaker honoraria from Allergan and Pfizer.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2006.094326v1
    2. 90/11/1370 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.